Literature DB >> 6174222

Stimulation of natural killer cell activity and inhibition of proliferation of various leukemic cells by purified human leukocyte interferon subtypes.

S H Lee, S Kelley, H Chiu, N Stebbing.   

Abstract

One of several human leukocyte interferon subtypes A (LeIF-A), obtained in purified form from a gene cloned in Escherichia coli, stimulated human peripheral blood natural killer cell activity, whereas another human leukocyte interferon subtype D (LeIF-D) had no effect with the use of K562 as target cells. With Daudi as target cells, both LeIF-A and LeIF-D stimulated natural killer cell activity. A hybrid human leukocyte interferon, NH2-terminal 61 amino acids and COOH-terminal 104 residues of LeIF-A and LeIF-D, respectively (LeIF-AD) showed greater stimulation than did LeIF-A, but the stimulation did not exceed that of natural buffy coat interferon. A mixture of equal antiviral units of LeIF-A and LeIF-D was no more effective than was LeIF-A alone. The cloned interferon subtypes showed differential effects on the proliferation of three human leukemic cell lines: Daudi (B-cell lymphoblastoid leukemia); BALL 1 (B-cell acute lymphoblastic leukemia); CCRF-HSB-2 (T-cell acute lymphoblastoid leukemia). Growth of Daudi cells was generally most sensitive to all the interferons tested, LeIF-A, -D, -AD, and a buffy coat preparation; no viable cells remained after 120-hr exposure to 1000-unit/ml doses of the interferons. BALL 1 was relatively resistant to the interferon subtypes tested including LeIF-AD, but this cell lines was very sensitive to a preparation of natural buffy coat interferon. CCRF-HSB-2 showed some sensitivity to all the interferons with greatest sensitivity to LeIF-A (10% of the viable cells were detected after 1000 units/ml exposure for 120 hr). In contrast to the leukemic cell lines tested, human amnion cells (WISH) and the human erythroid leukemia, K562, were resistant to the antiproliferative activity of the interferons.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6174222

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Regulation of cell proliferation and differentiation by interferons.

Authors:  M J Clemens; M A McNurlan
Journal:  Biochem J       Date:  1985-03-01       Impact factor: 3.857

2.  Alpha-interferon induces remission in hairy cell leukemia without enhancement of natural killing.

Authors:  G Gastl; W Aulitzky; E Leiter; R Flener; C Huber
Journal:  Blut       Date:  1986-05

Review 3.  Manipulation of host resistance in cancer therapy.

Authors:  R W Baldwin
Journal:  Springer Semin Immunopathol       Date:  1982

Review 4.  The optimal management of hairy cell leukaemia.

Authors:  R Gollard; T C Lee; L D Piro; A Saven
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

5.  Reduction of immunoglobulin G secretion in vitro following long term lymphoblastoid interferon (Wellferon) treatment in multiple sclerosis patients.

Authors:  M R O'Gorman; J Oger; L F Kastrukoff
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

6.  Antiviral effects of bacteria-derived human leukocyte interferons against encephalomyocarditis virus infection of squirrel monkeys. Brief report.

Authors:  N Stebbing; P K Weck; J T Fenno; D A Estell; E Rinderknecht
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

7.  Chemical synthesis of a human interferon-alpha 2 gene and its expression in Escherichia coli.

Authors:  M D Edge; A R Greene; G R Heathcliffe; V E Moore; N J Faulkner; R Camble; N N Petter; P Trueman; W Schuch; J Hennam
Journal:  Nucleic Acids Res       Date:  1983-09-24       Impact factor: 16.971

8.  Cloning, Transformation and Expression of Human Interferon α2b Gene in Tobacco Plant (Nicotiana tabacum cv. xanthi).

Authors:  Shahrzad Ahangarzadeh; Mohammad Hosein Daneshvar; Hamid Rajabi-Memari; Hamid Galehdari; Khalil Alamisaied
Journal:  Jundishapur J Nat Pharm Prod       Date:  2012-08-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.